Phillip Frost, M.D. presently serves as Chairman of the Board and Chief Executive Officer of OPKO Health, Inc. (NYSE: OPK), a specialty pharmaceutical company. He is Chairman of the Board of Directors of TEVA Pharmaceuticals, Ltd. (NASDAQ: TEVA), Ladenburg Thalmann Financial Services, Inc. (AMEX: LTS), and Prolor Biotech, Inc. (AMEX: PBTH) while also serving as a Director of Castle Brands, Inc. (AMEX: ROX). Previously, he served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation (AMEX: IVX) until its sale to TEVA for $8.5 billion, and Director of Continucare Corp. (NYSE: CNU) prior to its sale to Metropolitan Health Networks Inc. (AMEX: MDF). Dr. Frost also served as Chairman on the Board of Directors of IVAX Diagnostic (AMEX: IVD), and as Co-Vice Chairman of the American Stock Exchange (NYSE: NYX) and Northrop Grumman (NYSE: NOC). Dr. Frost serves on the Board of Regents of the Smithsonian Institution, is a member of the Board of Trustees of the University of Miami, Governor of Tel Aviv University, Chairman of Temple Emanu-El, and is a Trustee of each of the Scripps Research Institutes, the Miami Jewish Home for the Aged, and Mount Sinai Medical Center.
Phillip Frost, M.D.